Every 8-K that Drugs Made In America Acquisition II Corp. Right (DMIIR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow DMIIR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DMIIR filings page.
Drugs Made in America Acquisition II Corp. entered new agreements covering its finance and leadership roles. The company updated its Statement of Work with Titan Advisory Services LLC, which provides chief financial officer and principal accounting officer services through Saleem Elmasri.
Under the previously disclosed consulting arrangement, Mr. Elmasri’s services were tied to a $3,500 monthly fee and a grant or transfer of 100,000 ordinary shares upon engagement. The company also signed a CEO Compensation Agreement with Aleutian Equity Holdings LLC, the designated compensation vehicle for Chief Executive Officer Roger E. Bendelac, which includes customary indemnification, limitation of liability, dispute resolution, and governing law provisions.
Drugs Made In America Acquisition II Corp. entered into a Definitive Investment and Sponsor Transition Agreement with Alpha Multi Family Office to advance a contemplated $1,400,000 convertible notes financing. This follows an earlier unsecured Bridge Note of $150,000.
On March 30, 2026, the company issued an additional Interim Convertible Note, referred to as the Second Note, for $300,000. The Second Note matures nine months from issuance, carries no interest, and may be converted at the Investor’s option into shares of the post‑merger company at a 35% discount to the market price at conversion after the initial business combination closes.
The company plans to use the Second Note proceeds for accounting, audit, and other expenses related to completing its initial business combination, while the note itself constitutes a direct financial obligation of the company.
Drugs Made In America Acquisition II Corp. entered into a bridge financing and related letter of intent for up to $1,400,000 in convertible notes with Alpha Multi Family Office. The company issued an initial unsecured, zero‑interest Bridge Note for $150,000, maturing nine months after March 11, 2026, as the first tranche.
Upon completion of the initial business combination, the Bridge Note’s principal may be converted at the investor’s option into shares of the combined entity at a 35% discount to the market price at conversion. The letter of intent and addendum contemplate that the remaining $1,250,000 of funding, including an aggregate $400,000 by March 30, 2026, will be documented in a definitive convertible note purchase agreement. Proceeds are earmarked for accounting, audit, and other business combination expenses.
Drugs Made In America Acquisition II Corp. reported a leadership change following sponsor-related cash withdrawals from its working capital account. Between its September 2025 IPO and September 30, 2025, the sponsor withdrew an aggregate $1,100,000, including $325,000 to repay a working capital note and $208,000 for other offering costs and expenses.
An additional $566,269 appeared as an overpayment to the sponsor, and at least $200,000 was withdrawn to pay expenses described as unrelated to the company, together referred to as the Overpayment Amount. After the board directed the sponsor to return this Overpayment Amount and learned on February 12, 2026 that it would not be repaid, the board requested the resignation of CEO and executive chair Lynn Stockwell. Her resignation became effective February 28, 2026, and she was removed as CEO, executive chair, and director.
On February 28, 2026, the board appointed Roger Bendelac as Chief Executive Officer, effective upon Ms. Stockwell’s resignation. The company highlights Mr. Bendelac’s multi‑decade experience in investment banking, capital markets, and corporate advisory roles, and notes that his compensation terms will be determined and disclosed in a future filing.